ServiceUpdated on 13 August 2025
Cell Therapy Development & Manufacturing
About
If you need to produce a Cell Therapy, NecstGen offers a wide range of services and expert professionals, delivering a complete solution from start to end and providing unmatched access to scientific expertise.
Development:
-
Translational activities to create GMP compliant manufacturing
-
Process design and optimisation
-
Scale-up to clinically relevant volumes
-
Automation and closed processes
Manufacturing:
-
Pre-clinical or toxicology study material
-
Phase I to Phase III clinical trial material
Cell Therapies:
-
Induced Pluripotent Stem Cells (iPSCs)
-
Chimeric Antigen Receptor T-Cells, Tumor Infiltrating Lymphocytes (TIL), T-Cell Receptor Modified T-Cells (TCR-T)
-
Natural Killer (NK) Cells/CAR-NK Cells
-
Dendritic Cells (DC)
-
Mesenchymal Stromal Cells (MSC)
Furthermore, we offer process development and manufacturing for your desired viral vector.
We will be happy to discuss and help you bring your cell therapies to patients.
Type
- Development
- Manufacturing
Applies to
- Innovative therapies - Gene editing
- Innovative therapies - Somatic cell therapy
- Innovative therapies - Stem cell therapy
- Innovative therapies - Immune cell therapy
- Innovative therapies - Tissue engineered products
Similar opportunities
Service
Benefits of decentralized independent drug development for patients
- Others
- Development
- Innovative therapies - Gene editing
- Innovative therapies - Stem cell therapy
Marco Traub
CEO/CSO at TheSwissClinic-Society
Berne, Switzerland
Service
Viral Vector Development & Manufacturing
- Development
- Manufacturing
- Innovative therapies - Gene therapy
- Innovative therapies - Oncolytic viruses
Sophia Kolbe
Business Developer at NecstGen
Leiden, Netherlands
Product
EDDI - Epigenetic Digital Data Interface
- Innovative therapies - RNA therapy
- Innovative therapies - Gene therapy
- Innovative therapies - Gene editing
- Innovative therapies - Nanomedicine
- Innovative therapies - Stem cell therapy
- Innovative therapies - Oncolytic viruses
- Innovative therapies - Microbiome therapy
- Innovative therapies - Precision medicine
- Innovative therapies - Immune cell therapy
- Innovative therapies - Somatic cell therapy
- Innovative therapies - Tissue engineered products
- Innovative human-based test models - 3D spheroids
- Innovative human-based test models - 3D spheroids
- Innovative human-based test models - Organ-on-Chip
- Innovative human-based test models - In silico human models
- Development stages and support fuctions - Regulatory and compliance
- Innovative human-based test models - Bioprinted tissues and constructs
- Development stages and support fuctions - Data management and analytics
- Innovative human-based test models - Assembloids and multi-tissue models
- Development stages and support fuctions - Contract research (CRO / CRMO)
- Innovative human-based test models - 2D & 3D in vitro cell culture models
- Development stages and support fuctions - Early discovery / basic research
- Development stages and support fuctions - Funding, capital and investments
- Development stages and support fuctions - Ethics and social responsibility
- Development stages and support fuctions - Clinical research and development
- Development stages and support fuctions - Development and (GMP) manufacturing
- Development stages and support fuctions - Technology development and validation
- Development stages and support fuctions - Pre-clinical research and development
- Development stages and support fuctions - Commercial strategy and market access
daniel lüscher
CEO at QBDC GmbH
Nusshof, Switzerland